-葡萄糖共运输体2抑制剂和动脉样硬化
Alexandr Ceasovschih1,2, Anastasia Balta1, Essam Shams Aldeen1
1Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, Iasi, Romania.
American journal of preventive cardiology
|August 8, 2025
概括
-葡萄糖共运输体2抑制剂 (SGLT2i) 除了控制葡萄糖之外,还能为心血管提供显著的益处. 这些药物表现出动脉瘤保护作用并改善血管功能,使其在治疗动脉样硬化心血管疾病方面具有价值.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖共运输体2抑制剂 (SGLT2i) 是一种新的治疗类,具有已确定的心血管益处.
- 它们对动脉样硬化和相关血管疾病的影响需要全面的合成.
研究的目的:
- 审查SGLT2i对动脉样硬化,动脉硬性和相关心血管疾病的影响的临床和临床前证据.
- 阐明SGLT2i.的动脉保护优势背后的机制.
主要方法:
- 临床和临床前研究的系统审查.
- 关于SGLT2i对失脂症,冠状动脉疾病,外周动脉疾病和中风的影响的综合证据.
主要成果:
- SGLT2i通过多种机制表现出动脉保护作用,包括抗炎,抗氧化和改善血管功能.
- 益处扩展到血糖控制,减肥,血压管理和抗纤维作用.
- SGLT2i具有良好的安全性和与组合疗法的兼容性.
结论:
- SGLT2i提供广泛的心血管益处,显著影响动脉样硬化心血管疾病的管理.
- 这些药物正在推进心血管疾病护理的范式,具有有利的安全性.
- 积累的证据支持SGLT2i作为对抗动脉样硬化的关键药物.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
298
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
298
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
262
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
262
Glucose Transporters
24.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.1K
Dipeptidyl Peptidase 4 Inhibitors
260
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
260
Secondary Active Transport
7.6K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.6K
Oral Hypoglycemic Agents: Sulfonylureas
332
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
332


